BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12699351)

  • 1. The molecular targets of antitumor 2'-deoxycytidine analogues.
    Obata T; Endo Y; Murata D; Sakamoto K; Sasaki T
    Curr Drug Targets; 2003 May; 4(4):305-13. PubMed ID: 12699351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
    Obata T; Endo Y; Tanaka M; Uchida H; Matsuda A; Sasaki T
    Jpn J Cancer Res; 2001 Jul; 92(7):793-8. PubMed ID: 11473731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080.
    Obata T; Endo Y; Tanaka M; Matsuda A; Sasaki T
    Cancer Lett; 1998 Jan; 123(1):53-61. PubMed ID: 9461018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents.
    Verri A; Focher F; Priori G; Gosselin G; Imbach JL; Capobianco M; Garbesi A; Spadari S
    Mol Pharmacol; 1997 Jan; 51(1):132-8. PubMed ID: 9016355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine.
    Miwa M; Eda H; Ura M; Ouchi KF; Keith DD; Foley LH; Ishitsuka H
    Clin Cancer Res; 1998 Feb; 4(2):493-7. PubMed ID: 9516941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.
    Balzarini J; De Clercq E
    Mol Pharmacol; 1983 Jan; 23(1):175-81. PubMed ID: 6306422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
    Richel DJ; Colly LP; Arkesteijn GJ; Arentsen-Honders MW; Kerster MG; ter Riet PM; Willemze R
    Cancer Res; 1990 Oct; 50(20):6515-9. PubMed ID: 2208110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo.
    Yoshida T; Endo Y; Obata T; Kosugi Y; Sakamoto K; Sasaki T
    Drug Metab Dispos; 2010 Oct; 38(10):1814-9. PubMed ID: 20587622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential affinities of pyrimidine nucleoside analogues for deoxythymidine and deoxycytidine kinase determine their incorporation into murine leukemia L1210 cells.
    Balzarini J; De Clercq E
    Acta Biochim Pol; 1987; 34(2):63-77. PubMed ID: 2823514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate.
    Hughes TL; Hahn TM; Reynolds KK; Shewach DS
    Biochemistry; 1997 Jun; 36(24):7540-7. PubMed ID: 9200705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA; Boothman DA; Greer SB
    Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase.
    Eda H; Ura M; F-Ouchi K; Tanaka Y; Miwa M; Ishitsuka H
    Cancer Res; 1998 Mar; 58(6):1165-9. PubMed ID: 9515801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of deoxycytidine kinase by thymidine-5'-thiosulphate and release by deoxycytidine in human lymphocytes.
    Keszler G; Szikla K; Kazimierczuk Z; Spasokoukotskaja T; Sasvari-Szekely M; Staub M
    Biochem Pharmacol; 2003 Feb; 65(4):563-71. PubMed ID: 12566083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay.
    Kawasaki H; Shindou K; Higashigawa M; Cao DC; Hori H; Ido M; Sakurai M
    Leuk Res; 1996 Aug; 20(8):677-82. PubMed ID: 8913321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
    Kong XB; Tong WP; Chou TC
    Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.
    Bhalla K; Grant S
    Cancer Chemother Pharmacol; 1987; 19(3):226-32. PubMed ID: 3581416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine.
    Zhang M; Endo Y; Sasaki T
    Int J Oncol; 1999 Mar; 14(3):543-9. PubMed ID: 10024689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3'-amino-2',3'-dideoxycytidine and cytosine arabinoside.
    Mancini WR
    Cancer Chemother Pharmacol; 1992; 30(2):139-44. PubMed ID: 1318170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
    Ahluwalia GS; Cohen MB; Kang GJ; Arnold ST; McMahon JB; Dalal M; Wilson YA; Cooney DA; Balzarini J; Johns DG
    Cancer Res; 1986 Sep; 46(9):4479-85. PubMed ID: 2425954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.